Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of FOLFIRI plus bevacizumab versus FOLFIRI plus cetuximab in KRAS wild-type metastatic colorectal cancer
2012-000840-90Phase 2Completed
- Sponsor
- Spanish Cooperative Group for Digestive Tumour Therapy
- Start
- Apr 2012
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab, cetuximab, irinotecan, fluorouracil and folinic acid in metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by Spanish Cooperative Group for Digestive Tumour Therapy. Primary endpoint: Progression-free survival. Started Apr 2012; status: completed.
02
Drugs
bevacizumabcetuximabirinotecanfluorouracilfolinic acid
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2012-000840-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000840-90.